Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form
about
Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinaseCrystal Structures of Matriptase in Complex with Its Inhibitor Hepatocyte Growth Factor Activator Inhibitor-1Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironmentTissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasinRoles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptaseThe crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition.Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration.Roles of hepatocyte growth factor activator (HGFA) and its inhibitor HAI-1 in the regeneration of injured gastrointestinal mucosa.Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.Role of cancer cell-stroma interaction in invasive growth of cancer cells.SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing.Expression of flotillins in the human placenta: potential implications for placental transcytosis.Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itineraryTMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.Cleavage of hepatocyte growth factor activator inhibitor-1 by membrane-type MMP-1 activates matriptase.Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells.Crystal Structure of a Two-domain Fragment of Hepatocyte Growth Factor Activator Inhibitor-1: FUNCTIONAL INTERACTIONS BETWEEN THE KUNITZ-TYPE INHIBITOR DOMAIN-1 AND THE NEIGHBORING POLYCYSTIC KIDNEY DISEASE-LIKE DOMAIN.Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease.Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.The cytotrophoblast layer of human chorionic villi becomes thinner but maintains its structural integrity during gestation.Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1.Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy.Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1.Recombinant hepatocyte growth factor activator inhibitor 1: expression in Drosophila S2 cells, purification and crystallization.Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.Identification of antibodies against HAI-1 and integrin alpha6beta4 as immunohistochemical markers of human villous cytotrophoblast.
P2860
Q27636019-CFE37077-F6E5-4C64-A5B6-5633A9A8A38DQ27676642-3C4FA851-39D3-4A87-ACB0-3B2D768043F3Q28140022-90C918F3-9ED5-4E60-B7A4-5FD62ADDEFFAQ28180175-6CE9F5C9-1914-424C-9AC0-0696660FB109Q28267541-CC7D806F-7CCB-4740-A20C-F62EFB7BE571Q28572367-565102E3-47FF-418D-8EDB-75BC6F63F1FCQ30400406-29AD0D36-9FD6-4FC2-BC48-EE8C6190BF40Q34592412-E7E664B9-3208-4C94-A856-D31EE61B964EQ35062087-4FAD359A-82D3-4C01-B0B8-085DBAB5F256Q35084939-8D84CF64-F750-47A5-A4AA-9A28DBC7C519Q35217698-98435BED-548C-4564-B062-FB059C0B7452Q36329547-18679DDD-2D82-405D-9527-85C1BFCF9FA4Q36395707-26824BD9-8352-407A-AC66-D2FF05956F34Q36614877-8DA0D197-C806-4D97-9556-4041D8043290Q36753781-DE5ABAD4-499E-482B-AE39-9E29C5FABA69Q38339809-1352F997-B6AE-4EBB-81D7-D7F8D6229F42Q39437208-EA7F7157-6764-4D20-B55E-CCCED2B7DF3EQ39618840-496E3E89-616E-4AD9-8E86-2E7B1B7D0FE2Q39758360-2C9CFEC6-7FCB-45A5-91AF-D7EC74DDDA7DQ39782275-75DCB34C-F29B-4692-BBBE-6A50D402292BQ39816749-973C5F7D-2606-4E0E-A6AC-6930CA2E0476Q42399102-8DDF2987-2DC0-4451-9CC1-6A3A48E877C7Q42502623-A9BC3085-1A3C-4589-9E96-C4D9253B6B89Q43862930-2D1CEAB8-6C10-4C7B-9EE6-5649E2352B5AQ46918260-1DEBD7C9-AEE8-47EF-A77B-9E2740B39D9CQ47632003-01730CC4-4109-423F-8147-F7D8FF0B57C7Q51221442-E4248AA8-3E94-4B3C-A91E-D4DCDCA32B21Q51764334-D8B0DC8F-B956-43AE-B242-15667221816DQ52661781-7CA10C7B-C19D-4115-9A81-B960DA5B085DQ53635404-50826F0D-1A18-493E-86B3-B25AE25B0CFB
P2860
Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@ast
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@en
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@nl
type
label
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@ast
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@en
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@nl
prefLabel
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@ast
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@en
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@nl
P2093
P1476
Multiple sites of proteolytic ...... pe 1 from a transmembrane form
@en
P2093
K Matsumoto
K Miyazawa
N Kitamura
T Kawaguchi
T Shimomura
P356
10.1093/OXFORDJOURNALS.JBCHEM.A022522
P407
P577
1999-11-01T00:00:00Z